TEVA (Teva Pharma) Utang jangka cendhak marang modal

Teva Pharmaceutical Industries' efficiency is based on reducing its debt load and increasing sales of branded drugs. The trend of the short-term debt-to-equity ratio visualizes this process, where the 0.56 indicator determines this level. This has resulted in the stable operation of global plants and an end to the outflow of leading research scientists, which has strengthened the holding's operational resilience.

The short-term debt-to-equity ratio measures the proportion of liabilities maturing within one year relative to shareholders' equity, determining the business's reliance on short-term borrowing. An increase in this metric signals liquidity risk, whereas a decrease indicates conservative financial management. By analyzing the short-term debt-to-equity ratio trend, an investor assesses the stability of the financing structure. For Teva Pharmaceutical Industries (TEVA), this indicator is critically important during the implementation of its debt reduction strategy and the transition toward high-margin biosimilars.